Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Tirzepatide's unique dual mechanism of action targeting both GIP and GLP-1 receptors distinguishes it from other incretin-based therapies. The SURPASS-1 trial by Rosenstock, Wysham, Frias, and colleagues, published in The Lancet, was the first phase 3 trial to evaluate this novel dual agonist in patients with type 2 diabetes.

The double-blind, randomized phase 3 trial compared multiple doses of tirzepatide against placebo in patients with type 2 diabetes. The study assessed glycemic control, body weight changes, and safety over the treatment period, providing the foundational clinical evidence for tirzepatide's regulatory approval.

The SURPASS-1 trial confirmed tirzepatide's excellent efficacy and safety as a dual GIP/GLP-1 receptor agonist. The therapy achieved superior glycemic control in type 2 diabetes, with dose-dependent improvements that exceeded expectations based on single-receptor agonist experience.

This trial established the clinical foundation for tirzepatide and validated the dual-agonist approach to diabetes and metabolic treatment. For patients with type 2 diabetes, the SURPASS-1 results demonstrated that targeting two incretin pathways simultaneously can deliver meaningful advantages in glycemic control, setting the stage for tirzepatide's broader development in metabolic medicine.